Diabetes Devices Market Poised To Reach US$66,053.1 mn By 2025

Global Diabetes Devices and Drugs Market: SGLT-2 Inhibitors Segment to Expand at Impressive 76.80% CAGR from 2013 to 2019

The global diabetes devices and drugs market will expand at a moderate CAGR of 5.90% during the forecast period from 2013 to 2019, according to a report from Transparency Market Research (TMR). This report is titled "Diabetes Devices and Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019". In 2012, the global diabetes devices and drugs market was worth more than US$54.0 bn and by 2019, the market is projected to be worth US$83.0 bn.

Therapy-wise, the global diabetes devices and drugs market is segmented into insulin, non-insulin injectable anti-diabetes drugs, and oral anti-diabetes drugs. Long-acting insulin derivatives held a share of 42.7% in the global diabetes devices and drugs market in 2012. Among oral anti-diabetes drugs, the SGLT-2 inhibitors segment will witness a remarkable CAGR of 76.80% during the forecast period.

Report overview @ https://www.transparencymarketresearch.com/diabetes-devices-market.html

The global diabetes devices and drugs market is segmented into two segments, namely; diabetes devices and diabetes drugs class. Diabetes devices segment is divided into diabetes diagnostic and monitoring devices and insulin delivery devices. Diabetes diagnostic and monitoring devices class is further split into analog glucose meters, test strips, lancets and lancing devices, CGM devices and others. Insulin delivery devices class is divided into insulin pens, insulin syringes, insulin pumps and insulin injectors. The second segment of the market, that is, drugs class is fragmented into insulin derivatives, oral anti-diabetes drugs (OADs) and non insulin injectable anti-diabetes drugs. Insulin derivatives are categorized on the basis of their time of action, such as, rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Oral anti-diabetes drugs are divided into sulphonylureas, biguanides, meglitinides, alpha glucosidase inhibitors, thiazolidinediones, DPP-IV inhibitors, and SGLT2 inhibitors. GLP-1 agonists represent the injectable anti-diabetes drugs class. The report also provides in-depth analysis of pipeline diabetes drugs.

Summary of Table of Content

1. Introduction

2. Executive Summary

3. Disease Overview: Diabetes

4. Market Overview

5. Diabetes Devices Market, by Device Types

6. Global Diabetes Drugs Market, by Drug Therapy

7. Diabetes Devices and Drugs Market Revenue, by Geography

8. Competitive Landscape

Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=14<ype=S

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.